As per the latest reports from the experts, an effective drug to treat Alzeihmer’s disease will be available soon and also a vaccine to prevent Alzeihmer’s disease could also be available within a decade. Clinical trails on 12 drugs is being carried out which could be life-changing and the trials will be completed by 2021. […]
Luxturna FDA approval : Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics has secured the approval from the US Food and Drug Administration (FDA) for a rare inherited type of vision loss affecting children and adults that could result in blindness if left untreated. Luxturna is an adeno-associated viral (AAV) vector gene therapy which […]
Mylan has secured the US FDA approval for Estradiol Vaginal Cream USP, 0.01%, the generic version of Allergan’s vaginal estrogen cream – Estrace for the treatment of vulvar and vaginal atrophy. Following the approval of the vaginal estrogen cream, Mylan has announced the launch of Estradiol Vaginal Cream in the US. A condition that normally […]
Lilly gastric cancer drug Cyramza (ramucirumab) did meet the primary endpoint of a phase 3 trial RAINFALL but could not improve overall survival of patients.
Eli Lilly and Company, which is better known as Lilly, says that a late-stage trial of Cyramza (ramucirumab) for the treatment of a form of gastric cancer met its primary goal of stopping the disease from advancing, but failed in improving overall survival. An antiangiogenic therapy, ramucirumab in combination with cisplatin and capecitabine or 5-FU […]
Check out Repatha FDA approval news where we will tell you about the approval of the Amgen cholesterol drug for the prevention of heart attack and stroke.
Repatha FDA approval news : Repatha (evolocumab), the Amgen cholesterol drug has bagged the approval from the US Food and Drug Administration (FDA) for the prevention of heart attacks, strokes and coronary revascularizations in heart disease patients. The Amgen cholesterol injection is a human monoclonal antibody which has been designed to block the activities of […]
In the latest pharma industry news, ViiV Healthcare has bagged Juluca FDA approval for the maintenance treatment of virologically suppressed HIV-1 infection.
Juluca FDA approval : ViiV Healthcare’s 2-drug regimen Juluca has secured approval from the US Food and Drug Administration (FDA) for the maintenance treatment of virologically suppressed human immunodeficiency virus type 1 (HIV-1) infection. The HIV drug regimen Juluca, which is intended to be taken as a single pill daily once, is a combination of […]
Report on AstraZeneca blood cancer drug Calquence or acalabrutinib FDA approval for mantle cell lymphoma treatment in adult patients who had at least one prior therapy.
Acalabrutinib FDA approval : AstraZeneca has secured an early approval for its blood cancer drug Calquence (acalabrutinib) for the treatment of mantle cell lymphoma in adult patients who were subjected to a minimum of one prior therapy for the rare type of blood cancer. According to the National Cancer Institute at the National Institutes of […]
Kite Pharma has clinched the US FDA approval for its Car T therapy Yescarta (axicabtagene ciloleucel) for treating a type of lymphatic cancer in patients who have no more treatment options left and are staring at a dire prognosis.
Yescarta FDA approval : Kite Pharma has bagged the US FDA approval for its chimeric antigen receptor T cell (CAR T) therapy Yescarta (axicabtagene ciloleucel) for a type of lymphatic cancer (Lymphoma). FDA Approves New Lymphoma Drug Yescarta The Car T therapy from the Gilead subsidiary will be available as a new treatment option in […]
AstraZeneca lung cancer drug Tagrisso (osimertinib) for the treatment of non-small cell lung cancer (NSCLC) in a first line setting has been granted the breakthrough therapy designation by the by the US Food and Drug Administration.
Pharma news updates : Tagrisso (osimertinib), the AstraZeneca lung cancer drug has bagged the breakthrough therapy designation (BTD) from the US FDA for the treatment of non-small cell lung cancer (NSCLC) in a first line setting. The BTD designation for the AstraZeneca cancer drug is specifically for treating metastatic NSCLC patients who have tested positive […]
Luxturna FDA approval news : An FDA panel has recommended the approval of Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics for treating a rare form of genetically inherited form of blindness.
Luxturna FDA approval news : Luxturna (voretigene neparvovec), a gene therapy from Spark Therapeutics is closing in towards an FDA approval for treating blindness due to an inherited retinal disease (IRD), following the recommendation from an advisory panel of the US drug regulator. An adeno-associated viral (AAV) vector gene therapy, Luxturna has been recommended to […]